How Analysts Rated Revance Therapeutics Inc (NASDAQ:RVNC) Last Week?

June 20, 2017 - By Hazel Jackson

 How Analysts Rated Revance Therapeutics Inc (NASDAQ:RVNC) Last Week?
Investors sentiment increased to 1.78 in 2016 Q4. Its up 0.89, from 0.89 in 2016Q3. It improved, as 5 investors sold Revance Therapeutics Inc shares while 18 reduced holdings. 11 funds opened positions while 30 raised stakes. 21.34 million shares or 25.26% less from 28.55 million shares in 2016Q3 were reported.
Wells Fargo And Communications Mn invested 0% in Revance Therapeutics Inc (NASDAQ:RVNC). California State Teachers Retirement reported 0% in Revance Therapeutics Inc (NASDAQ:RVNC). Fmr Limited Liability Company reported 100,000 shares or 0% of all its holdings. Swiss Financial Bank has 0% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 30,750 shares. Arrowpoint Asset Mgmt Ltd Co invested in 0.66% or 2.02M shares. Tiaa Cref Mgmt Limited has 0% invested in Revance Therapeutics Inc (NASDAQ:RVNC). New Jersey-based State Of New Jersey Common Pension Fund D has invested 0% in Revance Therapeutics Inc (NASDAQ:RVNC). Wellington Llp has 2.15 million shares for 0.01% of their portfolio. 1.30 million were reported by Polar Cap Ltd Liability Partnership. Jpmorgan Chase Co owns 3.43 million shares or 0.02% of their US portfolio. Blackrock Institutional Na accumulated 0% or 516,855 shares. Franklin Resource holds 0.04% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC) for 3.28M shares. Adage Prtn Gru Ltd holds 0.02% or 350,000 shares in its portfolio. Bancshares Of Ny Mellon Corp invested in 0.01% or 1.94 million shares. Citigroup Inc has invested 0% in Revance Therapeutics Inc (NASDAQ:RVNC).

Since December 28, 2016, it had 0 buys, and 5 insider sales for $1.40 million activity. Another trade for 1,793 shares valued at $36,212 was made by SILVERNAIL LAUREN P on Monday, May 22.

Revance Therapeutics Inc (NASDAQ:RVNC) Ratings Coverage

Among 5 analysts covering Revance Therapeutics (NASDAQ:RVNC), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Revance Therapeutics had 6 analyst reports since August 22, 2015 according to SRatingsIntel. The rating was initiated by Aegis Capital on Tuesday, November 29 with “Buy”. Guggenheim initiated the stock with “Buy” rating in Monday, November 23 report. The firm earned “Hold” rating on Saturday, August 22 by Zacks. The rating was downgraded by Brean Capital on Tuesday, June 14 to “Hold”. The stock has “Buy” rating by SunTrust on Wednesday, March 23. Suntrust Robinson maintained the stock with “Buy” rating in Tuesday, June 14 report. Below is a list of Revance Therapeutics Inc (NASDAQ:RVNC) latest ratings and price target changes.

About 2,901 shares traded. Revance Therapeutics Inc (NASDAQ:RVNC) has risen 20.40% since June 20, 2016 and is uptrending. It has outperformed by 3.70% the S&P500.

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The company has market cap of $778.99 million. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. It currently has negative earnings. The Company’s peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection , or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

More notable recent Revance Therapeutics Inc (NASDAQ:RVNC) news were published by: Seekingalpha.com which released: “Revance Therapeutics’ (RVNC) CEO Dan Browne on Q1 2017 Results – Earnings Call …” on May 10, 2017, also Businesswire.com with their article: “Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All …” published on May 18, 2017, Seekingalpha.com published: “Revance Therapeutics’ (RVNC) CEO Dan Browne on Q4 2016 Results – Earnings Call …” on February 28, 2017. More interesting news about Revance Therapeutics Inc (NASDAQ:RVNC) were released by: Businesswire.com and their article: “Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery” published on June 15, 2017 as well as Prnewswire.com‘s news article titled: “Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of Revance …” with publication date: February 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.